Therefore, our results suggest that the enhancement of tumor suppression activity of anti-PD-1 antibody therapy combined with C/H treatment was mediated by CTL activation, which was a result of the increase of N1 TANs. This evidence concerns the gene PDCD1 and neoplasm.